Retatrutide

Retatrutide is a synthetic peptide and investigational triple hormone receptor agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors simultaneously. This tri-agonist mechanism distinguishes it from dual agonists like tirzepatide, and has positioned it as one of the most closely watched compounds in metabolic and obesity research. Early clinical data has suggested it may produce among the most significant weight reduction results observed in a peptide of its class to date.

Chemical Makeup Molecular Formula: C₂₅₆H₄₃₉N₇₃O₇₂ | Molecular Weight: ~4,859 g/mol | Also known as: LY3437943

Research Highlights

• Weight Reduction — Phase 2 clinical trials reported average body weight reductions of up to 24% over 48 weeks at higher doses, surpassing results observed with GLP-1 single agonists and positioning retatrutide as a leading candidate in obesity pharmacology research.
• Metabolic Function — By engaging all three receptors simultaneously, retatrutide may influence insulin secretion, hepatic glucose output, and energy expenditure in a complementary manner — with GLP-1 and GIP agonism supporting insulin regulation while glucagon receptor activation may promote increased caloric burn.
• Cardiovascular Markers — Early trial data suggested participants may experience improvements in blood pressure, triglyceride levels, and other cardiometabolic markers alongside weight reduction, though longer-term cardiovascular outcome studies are ongoing.
• Liver Health — Research indicates retatrutide's glucagon receptor activity may promote hepatic fat reduction, with studies exploring its potential in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) models.
• Appetite & Satiety Regulation — GLP-1 and GIP receptor engagement may slow gastric emptying and modulate hypothalamic satiety signaling, potentially reducing caloric intake and food-seeking behavior in research models.
• Bone & Muscle Preservation — Preliminary research has begun examining whether retatrutide's metabolic effects may be achieved while preserving lean muscle mass — a key consideration distinguishing next-generation receptor agonists from earlier weight loss compounds.

Available for research and laboratory purposes only.

Sonnet 4.6